Thiarabine News and Research

RSS
Thiarabine is a next generation nucleoside analogue. It has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity.
Access announces agreement to develop oral formulation of proprietary injectable drugs

Access announces agreement to develop oral formulation of proprietary injectable drugs

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

JCOM receives approval from KFDA to commercialize MuGard in Korea

JCOM receives approval from KFDA to commercialize MuGard in Korea

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

Access Pharmaceuticals to sell 2.10M shares in registered direct offering

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

Update on European commercial launch of MuGard for oral mucositis provided

Update on European commercial launch of MuGard for oral mucositis provided

Access Pharmaceuticals' update on its European commercial launch of Mugard

Access Pharmaceuticals' update on its European commercial launch of Mugard

iMedicor to market Access Pharmaceuticals' MuGard in North America

iMedicor to market Access Pharmaceuticals' MuGard in North America

Accupac to manufacture Access Pharmaceuticals' MuGard

Accupac to manufacture Access Pharmaceuticals' MuGard

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Thiarabine shows promise for rheumatoid arthritis

Thiarabine shows promise for rheumatoid arthritis